SCIENCE BEHIND COROQUIL-Zn

SCIENCE BEHIND COROQUIL-Zn

It has been established that the binding of the Spike S Protein of the SARS-CoV-2 virus to the host cell’s ACE2 receptor triggers a series of molecular events. This results in the entry of the virus into the host cell. The viral entry activates an immune response in the host to resolve the resulting infection. Depending on the magnitude and duration of the viral load and the time taken by the body to activate the immune response, the SARS-CoV-2 infection may result in asymptomatic / mild / moderate / severe COVID-19 disease. In critically ill patients it may even cause death.

COROQUIL-Zn is designed to counter the binding of the Spike S Protein of the SARS-CoV-2 virus to the ACE2 receptor. Thus the  entry of the virus to the host cell is blocked. The formulation of COROQUIL-Zn is the result of developing a series of cell-based experiments to study the activity of plant extracts. We have also conducted pilot experiments on hamsters. All the pre-clinical laboratory experiments were carried out in collaboration with the University of Missouri, USA.

COROQUIL-Zn, A BREAKTHROUGH DRUG

COROQUIL-Zn, A BREAKTHROUGH DRUG

cyrap

COVID-19 is a global pandemic caused by the SARS-CoV-2 virus. The virus enters the host epithelial cells of the lungs, gastrointestinal system, blood vessels and other organs via the ACE2 receptors in the cell. The viral entry is followed by viral replication – which leads to dysfunctional immune response and cytokine storm.  We used in silico molecular docking and cell-based studies to identify select phytoconstituents, that are present in different plants, for their ability to interfere with the binding of of the virus’ spike S protein’s receptor binding domain (RBD) with the host cell’s ACE2 receptor. We formulated COROQUIL-Zn using these identified plant extracts enriched with active phytoconstituents. By preventing the entry of SARS-COV-2 into the host cell, the viral replication is arrested. This results in the reduction of viral load and, hence, recovery from COVID-19.

COROQUIL-Zn INHIBITS ACE2 RECEPTOR ACTIVITY

            COROQUIL-Zn INHIBITS ACE2 RECEPTOR ACTIVITY

COROQUIL-Zn CLINICAL STUDIES

COROQUIL-Zn CLINICAL STUDIES

COROQUIL-Zn CLINICAL STUDIES

WHO Portal

CTRI Link

COROQUIL-Zn BENEFITS

COROQUIL-Zn BENEFITS

  • May control Virus multiplication
  • Overall viral load may reduce significantly
  • May result in faster recovery
  • May Reduce Hospitalization
  • Treatment does not require medical administration
  • Treatment dosage can be distributed into rural India
  • Treatment enhances Standard of Care treatment

COROQUIL-Zn PRODUCT DESIGN

COROQUIL-Zn PRODUCT DESIGN

  • Available in Capsule form
  • Formulated using edible plant extracts listed in Materia medica and
         Ayurvedic Pharmacopeia
  • Considered safe with no adverse effects
  • Derived from plants grown widely in Tamil Nadu
  • Contains Jasada Bhasma (Zinc Oxide)
  • Supports in modulating immunity against inflammatory diseases with
         respiratory distress, cough, fever, fatigue, sore throat, and gastrointestinal
         inflammation
  • Supports Respiratory System Function
  • Recovers Smell and Taste Function
  • May modulate ACE2 System Function

SCIENTIFIC ADVISORY BOARD

SCIENTIFIC ADVISORY BOARD

  • Dr. Kamlendra Singh, PhD (Molecular Interactions, University of Missouri, USA)
  • Dr. Ramesh Goyal, PhD, FIC, FAMS, FICN, FIPS, FNASc, FSCH, FIACS (VC, DPSRU)
  • Dr. Subbu Apparsundaram, PhD (Advisor, DPSRU)
  • Dr. Mahaveer Dhobi, PhD (Pharmacognosy, DPSRU)
  • Dr. Pavithra Venkatagopalan, PhD (Virology)
  • Dr. E G Rajan, PhD (Viral Genomics)

Contacts

© 2021, Remedium Therapeutics Private Limited. All Rights Reserved